A year of accelerating commercial traction offset by acute liquidity constraints—revenue surged 41% driven by FemBloc's European launch, yet the company faces a going concern warning with cash runway extending only to Q3 2026.
Key takeaways
Operating cash burn improved slightly to $18.7M from $19.4M prior year despite increased inventory investment.
FDA approved IDE supplement for final phase of FemBloc pivotal trial in November 2025, with enrollment initiated March 2026.